Why did Prometheus Biosciences (RXDX) stock surge today? - Kalkine Media

December 07, 2022 07:37 AM PST | By Rupam Roy
Follow us on Google News:

Highlights:

  • The RXDX stock was up over 180 per cent on Wednesday morning.
  • The company announced positive results from a clinical trial on December 7.
  • The stock's trading volume was up over 2.9 million during writing.

The stocks of the California-based biotechnology firm, Prometheus Biosciences, Inc. (NASDAQ: RXDX) were among the top percentage gainers on Wednesday, December 7. The RXDX stock soared more than 186 per cent soon after the trading commenced on Wall Street today.

So, what could have triggered the recent rally of the RXDX stock?

Let's take a quick tour of the recent developments and stock performances of the RXDX stock:

Why was it rising?

Prometheus Biosciences Inc. is a biotechnology firm, which focuses on the development of precision therapeutics for immune-mediated diseases. The clinical-stage biotechnology engages in discovering, developing, and commercializing novel therapeutics and companion diagnostic products for treating immune-mediated conditions.

The company's stock noted significant gains on Wednesday, after reporting positive results from the clinical trials of its product portfolio. The company said that it had generated results from ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies of PRA023 which demonstrates strong efficiency and favorable safety results in the studies.

Depending on the whole data from these studies, the California-based firm sought to advance its PRA023 into Phase 3 studies for colitis and Crohn's-related disorders in the coming year.

Investors might have lauded the announcement of the US$ 4.34 billion market cap firm. The company now aims to advance into pivotal development in 2023, after discussing with regulators.

Prometheus Biosciences said that it would present the full data sets from these two studies at a future medical meeting.

Third quarter earnings highlights of Prometheus BiosciencesSource: ©Kalkine Media®; © Canva via Canva.com

Bottom line:

The price of the RXDX stock was up 186.47 per cent at 9:38 am ET on December 7, to trade at US$ 103.3, while its trading volume was over 2.95 million at the same time. The stock closed at US$ 36.06 on December 6.

Meanwhile, Prometheus Biosciences' collaboration revenue was US$ 968,000 in Q3 FY22, as compared to US$ 1 million in Q3 FY21. The net loss of the firm deteriorated to US$ 37.27 million in Q3 FY22, from US$ 27.33 million in the year-ago period.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.



Top Listed Companies